Phase 2 Untreated Clinical Trials
12 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–12 of 12 trials
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled160 locationsNCT07221149
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled263 locationsNCT07221357
Recruiting
Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
High Risk Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blastsde Novo Myelodysplastic Syndrome+7 more
M.D. Anderson Cancer Center270 enrolled1 locationNCT00801489
Recruiting
Phase 1Phase 2
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Beat AML, LLC3,000 enrolled19 locationsNCT03013998
Recruiting
Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 2
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
Initial MZLUntreated MZLBTKi+1 more
Li Zhiming33 enrolled2 locationsNCT06985472
Recruiting
Phase 2
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Untreated Advanced or Recurrent Thymic Carcinomas
National Cancer Center, Japan35 enrolled1 locationNCT05832827
Recruiting
Phase 1Phase 2
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
DLBCLUntreatedMYC Gene Rearrangement
The First Affiliated Hospital with Nanjing Medical University81 enrolled1 locationNCT04432714
Completed
Phase 2
Investigating the role of targeted therapy Sorafenib - the Fms-like tyrosine kinase 3 (FLT3) inhibitor, in combination with intensive chemotherapy, for previously untreated adult patients with Acute Myeloid Leukaemia (AML) with FLT3 mutations. A Phase II randomised placebo-controlled multi-centre study
Previously untreated adult acute myeloid leukaemia (AML) with FLT3-ITD mutation.
Leukaemia Foundation of Australia102 enrolled15 locationsACTRN12611001112954
Completed
Phase 2
A Multicentre trial for the treatment of adolescents aged 15 years and above, and young adults aged up to 40 years, with newly diagnosed Acute Lymphoblastic Leukaemia (ALL)
Untreated ALL aged 15 to 40 years
Australasian Leukaemia and Lymphoma Group100 enrolled15 locationsACTRN12611000814976
Recruiting
Phase 2
A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with untreated multiple myeloma.
Untreated Multiple Myeloma patients with renal impairment.
Prof. Andrew Spencer28 enrolled1 locationACTRN12611000605998
Completed
Phase 2
Panobinostat with 5-azacytidine in patients with untreated high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML).
Previously untreated high risk Myelodysplastic syndrome (MDS)Previously untreated Acute Myeloid Leukaemia (AML)
The Alfred Hospital40 enrolled1 locationACTRN12610000924055